Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy

What this Trial Is About

This research aims to evaluate a combined treatment approach for adults with soft tissue sarcoma. The treatment involves three key steps: preoperative stereotactic radiation therapy delivered in hypofractionation mode, followed by surgery, and then postoperative conformal radiation therapy given in normofractionation mode. The study focuses on carefully targeting the tumor and surrounding tissues based on MRI and CT scans to optimize treatment planning while protecting normal tissues. The first step includes preoperative stereotactic radiation therapy administered in 5 fractions, with specific doses targeted to the tumor and nearby tissues planned from fused MRI and CT imaging. Surgery is scheduled 14 to 21 days after this radiation. Then, 25 to 35 days following surgery, postoperative conformal radiation therapy is delivered in 25 fractions according to a standard protocol, with target areas defined based on tumor bed and surrounding zones. The treatment aims to limit radiation exposure to normal tissues that remain after surgery. Participants will undergo detailed imaging and treatment planning before radiation therapy. They will receive radiation in two stages around the surgery, which occurs between the two radiation phases. Researchers will monitor complications over three years as the primary outcome and assess disease-free survival as a secondary outcome. The total follow-up duration extends to at least three years to evaluate treatment safety and effectiveness.

Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy